Be Biopharma Funding & Investors
Cambridge, MA
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
be.bioTotal Amount Raised: $356,000,000
Be Biopharma Funding Rounds
Series C
$92,000,000
Series C Investors
Bristol-Myers Squibb CompanyLongwood FundNextech InvestArch Venture PartnersAtlas VentureAlta PartnersRa Capital ManagementTakeda VenturesSeries Unknown
$82,000,000
Series Unknown Investors
Arch Venture PartnersTakeda VenturesRa Capital ManagementAtlas VentureAlta PartnersBristol-Myers Squibb CompanyLongwood FundSeries B
$130,000,000
Series B Investors
Arch Venture PartnersTakeda VenturesLongwood FundRa Capital ManagementAlta PartnersAtlas VentureBristol-Myers Squibb CompanySeries A
$52,000,000
Series A Investors
Atlas VentureRa Capital ManagementTakeda VenturesLongwood FundAlta Partners
Funding info provided by Diffbot.